A global research collaboration has been formalized between Novartis and Artios Pharma to target next-generation DNA damage response as Novartis builds up its radioligand therapies portfolio. Artios is eligible to receive $20 million as an upfront payment and up to $1.3 billion in milestone payments and sales aside from royalty payments.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.